Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

PPARγ Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice

Ryan, Michael J., Didion, Sean P., Mathur, Satya, Faraci, Frank M., Sigmund, Curt D. · 2004 · Hypertension

Abstract

The peroxisome proliferator activated receptor (PPARγ) agonist rosiglitazone has been reported to yield cardiovascular benefits in patients by a mechanism that is not completely understood. We tested whether oral rosiglitazone (25 mg/kg per day, 21 days) treatment improves blood pressure and vascular function in a transgenic mouse expressing both human renin and human angiotensinogen transgenes (R + A + ). Rosiglitazone decreased systolic (138±5 versus 128±5 mm Hg) and mean blood pressure (145±5 versus 126±7 mm Hg) of R + A + mice as measured by tail-cuff and indwelling carotid catheters, respectively. Relaxation of carotid arteries to acetylcholine and authentic nitric oxide, but not papaverine, was impaired in R + A + mice when compared with littermate controls (RA − ). There were no effects of rosiglitazone on RA − mice; however, relaxation to acetylcholine (49±10 versus 82±9% at 100 μmol/L) and nitric oxide (51±11 versus 72±6% at 10 μmol/L) was significantly improved in treated R + A + mice. Rosiglitazone treatment of R + A + mice did not alter the expression of genes, including endothelial nitric oxide synthase (eNOS), angiotensin 1 receptors, and preproendothelin-1, nor did it alter the levels of eNOS or soluble guanylyl cyclase protein. In separate studies, carotid arteries from R + A + and RA − mice relaxed in a concentration-dependent manner to rosiglitazone, suggesting possible PPARγ-independent effects in the vasculature. This response was not inhibited with the nitric oxide synthase inhibitor N ω -nitro- l -arginine methyl ester (200 μmol/L) or the PPARγ antagonist bisphenol A diglycidyl ether; 4,4′-isopropylidenediphenol diglycidyl ether (100 μmol/L). These data suggest that in addition to potential genomic regulation caused by PPARγ activation, the direct effect of rosiglitazone in blood vessels may contribute to the improved blood pressure and vessel function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.hyp.0000116303.71408.c2

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 184

Metadata

Authors
Ryan, M. J., Didion, S. P., Mathur, S., Faraci, F. M., & Sigmund, C. D.
Venue
Hypertension
Published
2004-03
Volume
43
Issue
3
Pages
661-666
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W2135606776
Cited by
184
References
2
FWCI
6.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PPARγ Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice. https://app.cochat.ai/papers/10.1161/01.hyp.0000116303.71408.c2
The paper
Ryan, M. J., Didion, S. P., Mathur, S., Faraci, F. M., & Sigmund, C. D. (2004). PPARγ Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice. Hypertension. https://doi.org/10.1161/01.hyp.0000116303.71408.c2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.